Screening for prostatic carcinoma.
Routine testing for prostatic carcinoma by digital rectal examination, transrectal ultrasonography and prostate specific antigen determination has been proposed to reduce deaths by earlier diagnosis. The questionable reliability of results, cost of screening, and inability to establish a balance between the benefits of treatment and the adverse effects on the quality of life of the men screened make screening experimental until controlled studies prove its value.
Hinman
F
F
Department of Urology, University of California School of Medicine, San Francisco 94l43-0738.
D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D003365:Costs and Cost Analysis; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000009:adverse effects / Q000191:economics; D010173:Palpation; D011379:Prognosis; D011467:Prostate / Q000000981:diagnostic imaging / Q000276:immunology; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000517:prevention & control*; D012007:Rectum; D014463:Ultrasonography
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen